PMID- 32399637
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210414
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 196
IP  - 9
DP  - 2020 Sep
TI  - Disease course of lung oligometastatic colorectal cancer treated with 
      stereotactic body radiotherapy.
PG  - 813-820
LID - 10.1007/s00066-020-01627-7 [doi]
AB  - PURPOSE: Stereotactic body radiotherapy (SBRT) or stereotactic ablative 
      radiotherapy (SABR) has been shown to increase survival rates in oligometastatic 
      disease (OMD), but local control of colorectal metastases remains poor. We aimed 
      to explore the natural course of oligometastatic colorectal cancer and to 
      investigate how SBRT of lung metastases can delay the progression to 
      polymetastatic disease (PMD). METHODS: 107 lung oligometastases in 38 patients 
      were treated with SBRT at a single institution. The median number of treated 
      lesions was 2 (range 1-5). Time to PMD (ttPMD) was defined as the time from SBRT 
      to the occurrence of >5 new metastases. Genetic biomarkers such as EGFR, KRAS, 
      NRAS, BRAF, and microsatellite instability were investigated as predictive 
      factors for response rates. RESULTS: Median follow-up was 28 months. At median 
      follow-up, 7 patients were free from disease and 31 had progression: 18 patients 
      had sequential oligometastatic disease (SOMD) and 13 polymetastatic progression. 
      All SOMD cases received a second SBRT course. Median progression-free survival 
      (PFS) was 7 months (range 4-9 months); median ttPMD was 25.8 months (range 
      12-39 months) with 1‑ and 2‑year PFS rates of 62.5% and 53.4%, respectively. 1‑ 
      and 2‑year local PFS (LPFS) rates were 91.5% and 80%, respectively. At univariate 
      analysis, BRAF wildtype correlated with better LPFS (p = 0.003), SOMD after 
      primary SBRT was associated with longer cancer-specific survival (p = 0.031). 
      Median overall survival (OS) was 39.5 months (range 26-64 months) and 2‑year OS 
      was 71.1%. CONCLUSION: The present results support local ablative treatment of 
      lung metastases using SBRT in oligometastatic colorectal cancer patients, as it 
      can delay the transition to PMD. Patients who progressed as SOMD maintained 
      a survival advantage compared to those who developed PMD.
FAU - Nicosia, Luca
AU  - Nicosia L
AUID- ORCID: 0000-0002-0731-8041
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy. 
      lucanicosia.rg@gmail.com.
FAU - Cuccia, Francesco
AU  - Cuccia F
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Mazzola, Rosario
AU  - Mazzola R
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Ricchetti, Francesco
AU  - Ricchetti F
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Figlia, Vanessa
AU  - Figlia V
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Giaj-Levra, Niccolo
AU  - Giaj-Levra N
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Rigo, Michele
AU  - Rigo M
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Tomasini, Davide
AU  - Tomasini D
AD  - Radiation Oncology Department, ASST Spedali Civili di Brescia, Brescia 
      University, Brescia, Italy.
FAU - Pasinetti, Nadia
AU  - Pasinetti N
AD  - Department of Radiation Oncology, Ospedale di Esine, ASL Valle Camonica-Sebino 
      Esine, Esine, Italy.
FAU - Corradini, Stefanie
AU  - Corradini S
AD  - Radiation Oncology Department, University Hospital, LMU Munich, Munich, Germany.
FAU - Ruggieri, Ruggero
AU  - Ruggieri R
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
FAU - Alongi, Filippo
AU  - Alongi F
AD  - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 
      Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
AD  - University of Brescia, Brescia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
CIN - Strahlenther Onkol. 2021 Jan;197(1):74-75. PMID: 33242138
CIN - Strahlenther Onkol. 2021 Jan;197(1):76-78. PMID: 33242139
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*radiotherapy/*secondary
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*pathology
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - *Radiosurgery
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Gastrointestinal cancer
OT  - Metatases directed therapy
OT  - Polymetastatic disease
OT  - SABR
OT  - Stereotactic ablative radiotherapy
EDAT- 2020/05/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1007/s00066-020-01627-7 [pii]
AID - 10.1007/s00066-020-01627-7 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2020 Sep;196(9):813-820. doi: 10.1007/s00066-020-01627-7. 
      Epub 2020 May 12.